A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

NCT00609921 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: ARQ197

Sponsor

Kyowa Kirin Co., Ltd.